Absolute Gestao de Investimentos Ltda. Has $320,000 Holdings in Eli Lilly and Company $LLY

Absolute Gestao de Investimentos Ltda. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 18.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387 shares of the company’s stock after buying an additional 60 shares during the quarter. Absolute Gestao de Investimentos Ltda.’s holdings in Eli Lilly and Company were worth $320,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Qtron Investments LLC raised its position in shares of Eli Lilly and Company by 9.2% during the first quarter. Qtron Investments LLC now owns 9,832 shares of the company’s stock worth $8,120,000 after purchasing an additional 826 shares during the period. Alpha Family Trust raised its position in shares of Eli Lilly and Company by 14.1% during the first quarter. Alpha Family Trust now owns 1,745 shares of the company’s stock worth $1,441,000 after purchasing an additional 215 shares during the period. Sand Hill Global Advisors LLC raised its position in shares of Eli Lilly and Company by 0.5% during the first quarter. Sand Hill Global Advisors LLC now owns 8,612 shares of the company’s stock worth $7,113,000 after purchasing an additional 44 shares during the period. Aptus Capital Advisors LLC raised its position in shares of Eli Lilly and Company by 10.6% during the first quarter. Aptus Capital Advisors LLC now owns 48,867 shares of the company’s stock worth $40,359,000 after purchasing an additional 4,687 shares during the period. Finally, Watts Gwilliam & Co. LLC raised its position in shares of Eli Lilly and Company by 119.7% during the first quarter. Watts Gwilliam & Co. LLC now owns 3,708 shares of the company’s stock worth $3,063,000 after purchasing an additional 2,020 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Leerink Partners reissued a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $950.17.

Eli Lilly and Company Stock Up 2.5%

LLY stock opened at $701.51 on Monday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $663.95 billion, a price-to-earnings ratio of 45.85, a PEG ratio of 0.98 and a beta of 0.44. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The stock has a fifty day moving average of $764.55 and a 200-day moving average of $794.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.92 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.